Medicina
September 28, 2008
Asta Kubilienė, Rūta Marksienė, Saulius Kazlauskas et al.
26 citations
Ibogaine is 2.4 times more toxic than noribogaine in mice. The median lethal dose (LD50) of ibogaine is 263 mg/kg of body mass, while noribogaine's LD50 is 630 mg/kg. At 500 mg/kg of ibogaine, all mice died; at 300 mg/kg, three out of four died; at 100 mg/kg, none died. For noribogaine, 500 mg/kg caused no deaths, 700 mg/kg killed three out of four, and 900 mg/kg killed all. Low doses of either substance did not affect mouse behavior; higher doses caused convulsions, nervous behavior, and limb paralysis.
Medicina
February 6, 2025
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea et al.
14 citations
A systematic review of 16 clinical trials from 2013 to 2023 found that psychedelic-assisted therapy, particularly with psilocybin and ayahuasca, can reduce alcohol and tobacco dependence, with psilocybin decreasing cravings and promoting long-term abstinence. Improvements in substance use reduction were significant when psychedelics were combined with psychotherapy. However, variability in dosages and study design calls for more standardized approaches. Regulatory barriers and specialized clinical training are needed to safely integrate these therapies into mainstream addiction treatment. Psychedelics offer a promising alternative for those unresponsive to conventional methods.
Medicina
May 9, 2023
Gniewko Więckiewicz, Julia Marek, Iga Stokłosa et al.
5 citations
A large Polish survey of 1,117 drug users found that marijuana, MDMA, and hallucinogenic mushrooms are the most commonly used substances, while amphetamine use is the most common reason for seeking medical help. Over 41 percent of respondents were receiving psychiatric treatment, with depressive disorders, anxiety disorders, and ADHD being the most frequent diagnoses. Compared to two years earlier, psilocybin and DMT use increased, heated tobacco product use rose, and the percentage receiving psychiatric help nearly doubled.